Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Bennouna, Jaafar; Sastre, Javier; Arnold, Dirk; Österlund, Pia; Greil, Richard; Cutsem, Éric Van; Moos, Roger von; Vieitez, José María; Bouché, Olivier; Borg, Christophe; Steffens, Claus-Christoph; Alonso-Orduña, Vicente; Schlichting, C.; Reyes-Rivera, Irmarie; Bendahmane, Belguendouz; André, Thierry; Kubicka, Stefan

doi:10.1016/s1470-2045(12)70477-1

Cited by 1,030 publications

(828 citation statements)

References 20 publications

Supporting

Mentioning

741

Contrasting

Unclassified

Order By: Relevance

“…At a median follow-up of 8.6 months, median survivals of patients following RE as a 2 nd -line, 3 rd -line, or 4 th -plus line therapy were 13.0 (range, 10.5-14.6), 9.0 (range, 7.8-11.0), and 8.1 (range, 6.4-9.3) months, respectively (8). These survival times compare favorably to those of patients treated with chemotherapy and other systemic therapies in similar settings (8)(9)(10)(11). This initial analysis concluded that 90 Y-RE appeared to have a favorable survival benefit for these patients.…”

Section: Introductionmentioning

confidence: 87%

Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases

Kennedy

Cohn

Coldwell

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: The Metastatic colorectal cancer liver metastases Outcomes after RadioEmbolization (MORE) study was a retrospective analysis of 606 patients with unresectable colorectal liver metastases treated with radioembolization (RE) using 90 Y-labeled resin microspheres. The first analysis of this study was completed with a last patient follow-up of 77.7 months. We now provide an updated survival analysis through September 15, 2016, with a last patient follow-up of 125 months. Methods: 90 Y-RE was considered for patients with advanced liver-only or liver-dominant metastatic colorectal cancer which was deemed not suitable for surgery, ablation, or systemic therapy, and which had progressed or become refractory to at least one line of systemic therapy. All patients with a diagnosis of metastatic colorectal cancer who had received at least 1 RE treatment and 1 follow-up visit were included in the analysis. Patients were treated between July 2002 and December 2011 at one of 11 U.S. tertiary care centers. Data were collected at baseline, on the day of the first 90 Y-RE treatment (day 0), and at all subsequent visits or until death. Patient medical charts and/or public records were accessed to obtain dates of death. Results: Dates of death were obtained for 574 out of a total of 606 patients, and overall survival (OS) data analyzed. Updated median OS was 10.0 months (95% CI: 9.2-11.8 months) at a median follow-up of 9.5 months versus the originally reported median OS of 9.6 months (95% CI: 9.0-11.1 months) at a follow-up of 8.6 months in the first MORE analysis. Patients received a median (range) of 2 (0 to 6) lines of chemotherapy. Baseline characteristics and factors significantly associated with patient survival (P<0.01) are consistent with those reported in the first safety analysis of the MORE study. These factors include poor ECOG performance status, markers of advanced disease such as increased extent of tumor-to-target liver involvement, poor baseline liver function, pre-treatment anemia, lung shunt fraction, and number of lines of prior chemotherapy. Patient age did not significantly affect survival outcomes. Conclusions: Long-term follow-up confirms that 90 Y-RE treatment offers favorable survival benefits for patients with unresectable metastatic colorectal cancer, even among patients who received 3 or more prior lines of chemotherapy. Our analysis also supports earlier reported prognostic factors for survival after 90 Y-RE. Overall, our updated analysis confirms that 90 Y-RE treatment provided a meaningful response and survival advantage for MORE patients across all ages and across diverse community and academic centers in the U.S.

show abstract

Section: Introductionmentioning

confidence: 87%

Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases

Kennedy

Cohn

Coldwell

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…Patienten, die in der Zweitlinientherapie Bevacizumab plus Chemotherapie erhielten, zeigten im Vergleich zur alleinigen Chemotherapie ein längeres medianes Gesamtüberleben 11,2 Monate (95 % CI, 10,4 -12,2) für Bevacizumab plus Chemotherapie und 9,8 Monate (95 % CI, 8,9 -10,7) für Chemotherapie allein (HR 0,81, p = 0,0062) [1164].…”

Section: Fortführung Der Anti-vegf-therapie In Der Zweitlinienbehandlungunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

148

View full text Add to dashboard Cite

“…In the clinic, after progression on a bevacizumab-containing regimen, bevacizumab is often continued fearing a rebound effect when stopping antiangiogenic therapy and data from metastatic colorectal cancer support this concept [104]. This clinical practice so far was lacking evidence from prospective and controlled clinical trials.…”

Section: Bevacizumab Monotherapy and Combination Regimensmentioning

confidence: 99%